Revolution Medicines, Inc. (RVMDW)
Revolution Medicines, Inc. (RVMDW)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net loss | -453,816 | -364,892 | -766,409 |
| Loss on disposal of fixed assets | NaN | 0 | -32 |
| Amortization of intangible assets | 0 | 69 | 801 |
| Stock-based compensation expense | 87,299 | 33,696 | 84,693 |
| Depreciation and amortization | 2,346 | 2,267 | 5,513 |
| Change in fair value of warrant liability | 15,788 | 12,627 | 2,731 |
| Non-cash interest expense on liabilities related to sale of future royalties | 12,197 | 11,937 | 12,294 |
| Net amortization of premium or discount on marketable securities | 3,223 | 4,554 | 23,277 |
| Amortization of operating lease right-of-use asset | 2,189 | 2,366 | 5,542 |
| Impairment of assets | NaN | NaN | 0 |
| Accounts receivable | NaN | 0 | 0 |
| Prepaid expenses and other current assets | 10,471 | 3,377 | 6,290 |
| Accounts payable | 16,857 | -10,501 | 20,036 |
| Accrued expenses and other current liabilities | -16,739 | 54,604 | 57,663 |
| Deferred revenue | NaN | 0 | NaN |
| Operating lease liability | -2,073 | 241 | -1,198 |
| Deferred tax liability | NaN | 0 | NaN |
| Long-term deposits | 10,561 | 7,297 | 4,723 |
| Other noncurrent assets | NaN | 154 | 12,718 |
| Other prepaid and noncurrent assets | 378 | NaN | NaN |
| Other noncurrent liabilities | 5,664 | -1,270 | 1,807 |
| Net cash used in operating activities | -354,165 | -274,238 | -623,503 |
| Purchases of marketable securities | 209,733 | 296,485 | 1,498,365 |
| Maturities of marketable securities | 383,886 | 373,292 | 1,549,222 |
| Sales of marketable securities | NaN | 0 | 6,384 |
| Purchases of property and equipment | 1,538 | 1,925 | 14,065 |
| Proceeds from issuance of common stock pursuant to stock option exercises | NaN | 21,134 | NaN |
| Net cash provided by (used in) investing activities | 172,615 | 74,882 | 43,176 |
| Proceeds from issuance of common stock related to employee stock purchase plan | NaN | 3,392 | 4,644 |
| Cash, cash equivalents and restricted cash acquired in connection with eqrx acquisition, net of transaction costs | NaN | 0 | NaN |
| Proceeds from the sale of future royalties, net of issuance costs | NaN | 0 | 244,215 |
| Proceeds from issuance of common stock, net of issuance costs | NaN | 0 | NaN |
| Proceeds from issuance of pre-funded warrants, net of transaction costs | NaN | 0 | NaN |
| Proceeds from issuance of common stock upon at-the-market offering, net of issuance costs | 226,730 | 347,915 | 0 |
| Tax payment for common stock withheld in satisfaction of withholding tax requirements | NaN | 0 | NaN |
| Proceeds from issuance of common stock under equity incentive plans | 5,236 | NaN | 6,973 |
| Exercise of warrants | 57 | 0 | 4 |
| Deferred offering costs | 252 | -191 | -29 |
| Net cash provided by financing activities | 238,744 | 365,659 | 255,865 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 57,194 | 166,303 | -324,462 |
| Cash, cash equivalents and restricted cash - beginning of period | 388,603 | 222,300 | 546,762 |
| Cash, cash equivalents and restricted cash - end of period | 445,797 | 388,603 | 222,300 |